NTLX.V NeuroThera Labs Inc.

Healthcare Drug Manufacturers - General TSX Venture Exchange
1.61 CAD
Close of Nov 7, 2026
1.61 5.32
Market cap
CAD 137M
P/E
-
P/B
5.07x
ROE
-3,076.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Jan 2026.

Is NTLX.V undervalued?

Graham number

The Graham number of NeuroThera Labs Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

NeuroThera Labs Inc. fundamental analysis

No fundamental analysis for NeuroThera Labs Inc. yet.

NeuroThera Labs Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About NeuroThera Labs Inc.

Neurothera Labs Inc. engages in the development of a portfolio of drugs based on cannabinoid molecules. The company develops programs based on tetrahydrocannabinol (THC) and/or non-psychoactive cannabidiol for the treatment of Tourette syndrome, Alzheimer's disease and agitation, autism spectrum disorder, and status epilepticus. It also focuses on e-commerce operations, which sells hemp-based products. Neurothera Labs Inc. was formerly known as Miza III Ventures Inc. The com…

Full company profile